证券代码：688315 证券简称：诺禾致源 公告编号：2024-043 北京诺禾致源科技股份有限公司 关于增加募投项目实施主体后 重新签订募集资金专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京诺禾致源科技股份有限公司向特 定对象发行股票注册的批复》（证监许可【2022】2813 号）同意，北京诺禾致源 科技股份有限公司（以下简称"公司"或"诺禾致源"）向特定对象发行 16,000,000 股 A 股股票，每股发行价格 20.76 元，共募集资金人民币 332,160,000.00 元，扣 除不含增值税的发行费用人民币 4,551,356.60 元后，实际募集资金净额为人民币 327,608,643.40 元。上述募集资金到位情况已经立信会计师事务所（特殊普通合 伙）审验，并出具了《北京诺禾致源科技股份有限公司向特定对象发行 A 股股票 募集资金验资报告》（信会师报字[2023]第 ZG11941 号）。 二、重新签订《募集资金专户存储 ...

[Table_MainInfo] 公司研究/医药与健康护理/医疗保健提供商与服务 证券研究报告 诺禾致源（688315）公司半年报点评 2024 年 08 月 20 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |-------------------------------------------------|--------------------| | 股票数据 | | | 08 [ Table_StockInfo 月 19 日收盘价（元） ] | 10.44 | | 52 周股价波动（元） | 9.63-26.60 | | 总股本 / 流通 A 股（百万股） | 416/416 | | 总市值 / 流通市值（百万元） | 4345/4345 | | 相关研究 | | | [Table_ReportInfo] 《国内经营承压， | 海外营收稳中有升》 | | 2024.04.23 | | | 《盈利能力承压，公司单三季度净利率略有下 | | | 滑》 2023.12.25 | | 市场表现 [Table_QuoteInfo] -56.95% -41.95 ...

Investment Rating - The report maintains a "Recommended" rating for the company [4]. Core Views - The company has shown stable recovery in performance, with a revenue of 999.7 million yuan (+7.18%) and a net profit of 78 million yuan (+3.86%) for the first half of 2024. The second quarter of 2024 saw revenues of 528 million yuan (+7.94%) and a net profit of 51 million yuan (-3.66%) [2][3]. - The company is enhancing its global service capabilities and scale, with significant investments in new sequencing systems to meet the latest sequencing demands [2]. - The company is expanding its multi-omics service offerings, which is expected to improve profitability. R&D investment for the first half of 2024 was 47 million yuan, accounting for 4.68% of revenue [2][3]. Financial Performance Summary - For the first half of 2024, the company reported a revenue of 999.7 million yuan, with a breakdown of 496 million yuan from mainland China (+6.27%) and 501 million yuan from Hong Kong, Macau, Taiwan, and overseas (+8.09%) [2]. - The revenue structure shows that life sciences basic research services accounted for 34.44% of total revenue, while sequencing platform services made up 48.90% [2]. - The company’s gross margin slightly improved to 41.71% due to enhanced operational efficiency and automation [2][3]. Financial Forecasts - The revenue forecasts for 2024-2026 have been adjusted to 2.238 billion yuan, 2.662 billion yuan, and 3.165 billion yuan, respectively, with corresponding net profits of 205 million yuan, 256 million yuan, and 320 million yuan [3][8]. - The expected EPS for 2024, 2025, and 2026 are 0.49 yuan, 0.62 yuan, and 0.77 yuan, respectively, with PE ratios of 22, 17, and 14 times [3][8].

我是农合资源财务总监石家山下面由我代表公司来汇报一下2024年Q2的业绩情况我们公司2024年Q2收入保持增长增速持续提升2024年Q2实现营收5.28亿元同比增长7.94% 本比增速提升1.62个百分点上每年累计实现营收9.97亿元同比增长7.18%公司2024年Q2境外客户收入因美洲区、欧洲区侦探平台逐步稳定我们收入增速逐步恢复 2020Q2的境外客户实现营收2.65亿元同比增长13.91%反比增速提升11.67个百分点上半年境外客户累计实现营收5.01亿元同比增长8.09%但公司总营收比50.26%同比 营收比重上升0.42个百分点公司2024年Q2国内客户因企业内客户信用的收紧短期内增速与波动2024年Q2国内客户实现营收2.64亿元同比增长2.55%上半年累计实现营收4.96亿元 以下整体帧数存在一些差异生命科学类生命科学基础科研服务实现营收1.84亿元同比增长14.66%监控车序平台服务类实现营收2.58亿元同比增长12.66%医学类的 医学研究与技术服务类实现营收0.69亿元同比下降6.8%从客户类型上看仍然以高校和研究机构收入为主2024年Q2整体权重有上升高校研究机构 零收2024年Q2占总 ...

Group 1: Financial Performance - The company achieved a revenue of 9.97 billion CNY in the first half of 2024, representing a growth of 7.18% compared to 9.30 billion CNY in the same period of 2023 [3][4]. - Revenue from overseas clients reached 5.01 billion CNY, a year-on-year increase of 8.09%, accounting for 50.26% of total revenue [4]. - The net profit attributable to shareholders was 7,792.69 thousand CNY, reflecting a growth of 3.86% year-on-year [6]. Group 2: Operational Insights - The global capacity utilization rate is approximately 70%, with some fluctuations during the transition between old and new platforms [4][8]. - The company has established local laboratories in the USA, UK, Singapore, Germany, and Japan, which are now in stable operation [5][7]. - The average capacity utilization rate across global laboratories is also around 70% [8]. Group 3: Market Strategy - The company plans to expand its product offerings to existing clients while increasing the variety of services for new clients [5]. - Marketing investments are being increased, including traditional sales and digital marketing strategies [5]. - The company is focusing on automation to enhance production efficiency and maintain competitiveness [7].

证券代码：688315 证券简称：诺禾致源 公告编号：2024-041 北京诺禾致源科技股份有限公司 关于持股 5%以上股东权益变动比例达到 1%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次权益变动属于股份减持，不触及要约收购。 | 信 | 息 | 名称 | 北京诺禾禾谷投资管理中心（有限合伙） | | --- | --- | --- | --- | | 义 | 务 | 企业类型 | 有限合伙 | | 披 | 露 | 执行事务合 | 李瑞强 | | 人 | 基 | 伙人 | | | 本 | 信 | 注册地址 | 北京市海淀区学清路 38 号 B 座 2106 室 | | 息 | | | | | 信 | 息 | 姓名 | 李瑞强 | | 义 | 务 | | | | 披 | 露 | 性别 | 男 | | 人 | 基 | | | | 本 | 信 | 国籍 | 中国 | | 息 | | | | 2、本次权益变动情况 | 股东名称 | 变动方式 | 变动日期 | | 股份种类 | 减持股数 ...

| --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 12.61 CNY per share based on a PE of 25X for 2024 [3]. Core Insights - The company reported a revenue of 999.7 million CNY for the first half of 2024, representing a year-on-year increase of 7.18%. The net profit attributable to shareholders was 77.93 million CNY, up 3.86%, while the net profit excluding non-recurring items was 65.91 million CNY, reflecting a growth of 12.92% [1]. - The performance showed a positive trend with all three major business segments recovering to varying degrees. The revenue for Q1 and Q2 of 2024 was 468 million CNY and 528 million CNY, respectively, with year-on-year increases of 6.32% and 7.94% [1]. - The company is expanding its global presence, having established laboratories in various countries including Japan, and now serves nearly 7,300 clients across approximately 90 countries and regions [1]. Financial Summary - The company expects its net profit attributable to shareholders to reach 210 million CNY, 249 million CNY, and 293 million CNY for the years 2024, 2025, and 2026, respectively [2]. - Revenue projections for the upcoming years are 2.211 billion CNY for 2024, 2.512 billion CNY for 2025, and 2.858 billion CNY for 2026, with growth rates of 10.4%, 13.6%, and 13.8% respectively [2]. - The EBITDA is projected to be 394 million CNY in 2024, increasing to 541 million CNY by 2026 [2].

本报告仅供 Choice 东方财富 使用，请勿传阅。 2024 年 08 月 15 日 诺禾致源(688315.SH) 业绩平稳增长，持续优化基础设施 事件： 2024 年 8 月 14 日，公司发布 2024 年中期报告。2024 年上半年公 司实现营业收入 9.97 亿元，同比增长 7.18%；实现归母净利润 0.78 亿元，同比增长 3.86%；实现扣非归母净利润 0.66 亿元，同比增长 12.92%。单季度来看，2024 年 Q2 公司实现营业收入 5.28 亿元， 同比增长 7.94%；实现归母净利润 0.51 亿元，同比下降 3.66%；实 现扣非归母净利润 0.45 亿元，同比增长 16.06%。 境内外收入平稳增长，盈利水平保持稳定。 2024 年上半年公司整体营业收入增长相对平稳：分区域来看，2024 年上半年中国大陆实现营收 4.96 亿元，同比增长 6.27%；港澳台及 海外地区实现营收 5.01 亿元，同比增长 8.09%。2024 年上半年公司 盈利水平保持稳定：2024H1 整体毛利率 41.71%，同比增加 0.14pct， 其中中国大陆毛利率 41.16%，港澳台及海外地区毛 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with a year-on-year growth of 25%[1]. - The company's operating revenue for the first half of 2024 was ¥996,652,714.08, representing a 7.18% increase compared to ¥929,924,087.18 in the same period last year[17]. - The net profit attributable to shareholders for the first half of 2024 was ¥77,926,867.87, a 3.86% increase from ¥75,033,954.45 in the previous year[17]. - The net profit attributable to shareholders was 77.93 million yuan, reflecting a year-on-year increase of 3.86% due to higher gross profit from increased revenue[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 65.91 million yuan, up 12.92% year-on-year, influenced by increased gross profit and a reduction in other income due to the expiration of VAT rebate policies[19]. - The company's cash flow from operating activities was -82.34 million yuan, compared to -4.51 million yuan in the same period last year, primarily due to short-term fluctuations in revenue collection and changes in tax payments[19]. - The company's net cash flow from operating activities was -82,343,309.23 RMB, a decline from -4,513,503.04 RMB in the previous period, indicating a worsening operational cash flow situation[142]. - The company achieved operating revenue of CNY 996.65 million, a year-on-year increase of 7.18%[58]. - The net profit attributable to shareholders was CNY 77.93 million, reflecting a growth of 3.86% year-on-year[58]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 65.91 million, up 12.92% year-on-year[58]. Research and Development - The company is investing in R&D, with a budget increase of 30% for new technologies and product development[1]. - The R&D expenditure as a percentage of operating revenue was 4.68%, a decrease of 0.66 percentage points from 5.34% in the previous year[18]. - The company invested CNY 46.6151 million in R&D, accounting for 4.68% of its revenue[33]. - Research and development expenses amounted to CNY 46.62 million, representing 4.68% of operating revenue[58]. - The company has developed a new product for transcription regulation and three-dimensional genome analysis, with an expected total investment of ¥10,229.31 million and a current investment of ¥237.62 million[37]. - The automation of bioinformatics processes is in the development stage, with a current investment of ¥306.66 million and a total investment of ¥8,409.75 million[37]. - The company has developed a new pathogen detection product that can complete nucleic acid testing in just a few minutes, with a project investment of CNY 1,656.15 million[40]. Market Expansion and Strategy - The company provided a positive outlook for the second half of 2024, projecting a revenue growth of 20%[1]. - Market expansion plans include entering two new international markets by the end of 2024[1]. - The company is considering strategic acquisitions to enhance its market position, with a focus on complementary technologies[1]. - The company has established collaborations with numerous top-tier hospitals for its pathogen metagenomics high-throughput detection products[31]. - The company is actively expanding its product line in tumor, genetic, and infectious disease testing, aiming for collaborative growth across multiple sectors[51]. Operational Efficiency - The company employs an order-based production model, analyzing historical project data to forecast production plans and allocate capacity accordingly[23]. - The company has implemented a full-process data real-time monitoring system in library construction, sequencing, and bioinformatics analysis to ensure data quality[25]. - The company has established a high-performance data center with a total memory of approximately 92TB and local storage of about 22.5PB, supporting big data analysis and storage needs[26]. - The company has achieved a microbial extraction amplification pass rate of 98.69% for various sample types, including soil and swabs[25]. - The company has automated standard library construction processes and accumulated rich experience in differentiated processing for non-standard library construction[25]. Governance and Compliance - The board confirmed that all directors attended the board meeting, ensuring governance compliance[1]. - The management highlighted the importance of risk management strategies to mitigate potential operational risks[1]. - The company has no significant non-operational fund occupation by controlling shareholders[1]. - The company has not reported any changes in its registered address or contact information during the reporting period[13][14]. - The company has ensured compliance with all commitments made during its initial public offering, with no reported delays or issues[84]. Financial Position - The total assets at the end of the reporting period were ¥3,387,809,821.41, down 5.75% from ¥3,594,420,954.11 at the end of the previous year[17]. - The net assets attributable to shareholders decreased by 3.13% to ¥2,380,641,463.42 from ¥2,457,457,998.48 at the end of the previous year[17]. - The company's total assets include overseas assets amounting to 1,106,115,434.81 RMB, accounting for 32.65% of total assets[64]. - The total liabilities decreased to approximately ¥986.84 million from ¥1.12 billion, a reduction of about 11.9%[131]. - The total equity attributable to shareholders decreased to approximately ¥2.38 billion from ¥2.46 billion, reflecting a decline of about 3.1%[131]. Product Development and Innovation - The company has established a leading gene sequencing platform, leveraging multi-omics research techniques for life sciences and clinical applications[21]. - The company has developed over ten agricultural trait detection chips, providing efficient and cost-effective services for breeders[27]. - The company has developed a micro-library production system for Hi-C three-dimensional research, achieving a sample input of 200mg and a cell input of 5000 cells, significantly improving sequencing data efficiency[28]. - The company has made significant advancements in single-cell sequencing technology, including the integration of spatial transcriptomics and spatial proteomics services[29]. - The company has developed a strategy for sub-genomic allele expression preference analysis to understand the complex regulatory processes in polyploid genomes[30]. Environmental Responsibility - The company is committed to environmental responsibility, adhering to national standards for waste management[79]. - The company has implemented measures to manage wastewater, including treatment of low-concentration wastewater and high-concentration hazardous waste by qualified units[80]. - The company has established facilities for the treatment of volatile organic compounds (VOCs) and ensures compliance with industrial emission standards[80]. - The company has committed to long-term environmental responsibilities, including proper disposal of solid waste and hazardous materials[80]. Shareholder Commitments - The company has ongoing commitments from major stakeholders to address related party transactions and competition issues, effective since February 19, 2021[82]. - The company has a long-term commitment to maintain share restrictions for its directors and senior management, effective for 12 to 36 months post-IPO[83]. - The company guarantees that all commitments made are true, accurate, and complete, with legal responsibilities for any misrepresentation[88]. - The company will ensure compliance with new regulatory requirements regarding compensation measures if they arise[26].